

Barbara A Santevecchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/114752/publications.pdf>

Version: 2024-02-01

13
papers

55
citations

1684188

5
h-index

1720034

7
g-index

13
all docs

13
docs citations

13
times ranked

36
citing authors

#	ARTICLE	IF	CITATIONS
1	In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy158.	0.9	20
2	Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population Pharmacokinetics. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0204621.	3.2	9
3	Implementation of a β -lactam therapeutic drug monitoring program: Experience from a large academic medical center. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 1586-1591.	1.0	9
4	Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Na ⁻ ve Adults With HIV-1 Infection. <i>Annals of Pharmacotherapy</i> , 2020, 54, 1252-1259.	1.9	7
5	Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase-producing Enterobacterales bloodstream infections (REDUCE-BSI). <i>Antimicrobial Stewardship & Healthcare Epidemiology</i> , 2022, 2, .	0.5	5
6	Implementation of a comprehensive intervention focused on hospitalized patients with HIV by an existing stewardship program: successes and lessons learned. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110105.	1.8	2
7	Impact of Empiric Linezolid for Necrotizing Soft Tissue Infections on Duration of Methicillin-Resistant Staphylococcus aureus-Active Therapy Empiric Linezolid Use for Necrotizing Soft Tissue Infections. <i>Surgical Infections</i> , 2022, , .	1.4	2
8	Impact of supplemental individual verbal defense on confidence, engagement, and performance in a team-based learning therapeutics course. <i>Currents in Pharmacy Teaching and Learning</i> , 2021, 13, 152-158.	1.0	1
9	1576. Re-Evaluation of cefepime or piperacillin-tazobactam to Decrease Use of Carbapenems in ESBL-Producing <i>Enterobacterales</i> BloodStream Infections (REDUCE-BSI). <i>Open Forum Infectious Diseases</i> , 2020, 7, S786-S787.	0.9	0
10	143. Modification of Linezolid Restriction Criteria Reduces ICU Gram-positive Antibiotic Consumption. <i>Open Forum Infectious Diseases</i> , 2020, 7, S201-S202.	0.9	0
11	Pharmacy student self-assessment of strength of residency candidacy compared to clinical faculty. <i>Currents in Pharmacy Teaching and Learning</i> , 2022, 14, 304-309.	1.0	0
12	1257. Re-Evaluation of Cefepime or Piperacillin-Tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales Urinary Tract Infections (REDUCE-UTI). <i>Open Forum Infectious Diseases</i> , 2021, 8, S717-S718.	0.9	0
13	1101. Implementing a Beta-Lactam Therapeutic Drug Monitoring Program: Experience from a Large Academic Medical Center. <i>Open Forum Infectious Diseases</i> , 2021, 8, S642-S642.	0.9	0